These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2908732)

  • 1. Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.
    Frishman WH
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):343-53. PubMed ID: 2908732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of labetalol, the first alpha- and beta-blocking agent.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):617-28. PubMed ID: 2867049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha- and beta-blockade in angina pectoris.
    Taylor SH
    Drugs; 1984; 28 Suppl 2():69-87. PubMed ID: 6151892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Labetalol: an alpha- and beta-blocker.
    Conner CS
    Drug Intell Clin Pharm; 1983; 17(7-8):543-4. PubMed ID: 6135593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential hemodynamic effects of beta-adrenoceptor blockers, Ca antagonists and combined alpha-beta-receptor blockade in ischemic heart disease.
    Koch G
    Acta Med Scand; 1986; 219(1):17-22. PubMed ID: 2869648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses.
    Prida XE; Hill JA; Feldman RL
    Am J Cardiol; 1987 May; 59(12):1084-8. PubMed ID: 2883869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
    Roberts DH; Tsao Y; Grimmer SF; Winstanley PA; Orme ML; Breckenridge AM
    Br J Clin Pharmacol; 1987 Aug; 24(2):163-72. PubMed ID: 2887190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of combined alpha-beta-blockade. I.
    Louis WJ; McNeil JJ; Drummer OH
    Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Labetalol in the treatment of angina pectoris.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):166-74. PubMed ID: 2881899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):369-76. PubMed ID: 3154919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and coronary hemodynamic effects of combined oral alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests.
    Feldman RL; Prida XE; Hill JA
    Clin Cardiol; 1988 Jun; 11(6):383-8. PubMed ID: 3396239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of combined alpha/beta-adrenoceptor blockade v combined beta-receptor and slow channel calcium blockade in ischemic heart disease complicated by hypertension. Hemodynamic and adrenergic responses.
    Koch G; Fransson L
    Am J Hypertens; 1991 Aug; 4(8):709-13. PubMed ID: 1681821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha- and beta-receptor blocking drugs in the treatment of hypertension.
    Ram CV; Kaplan NM
    Curr Probl Cardiol; 1979 Jan; 3(10):1-53. PubMed ID: 40755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade.
    Lubbe WF; White DA
    Clin Sci Mol Med Suppl; 1978 Dec; 4():283s-286s. PubMed ID: 32006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labetalol: an alpha- and beta-adrenoceptor blocking drug.
    Michelson EL; Frishman WH
    Ann Intern Med; 1983 Oct; 99(4):553-5. PubMed ID: 6137987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease.
    Feldman RL; Prida XE; Lambert CR; Hill JA
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):355-61. PubMed ID: 3155428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.